DelveInsight's "VERZENIO Market Size, Forecast, and Market Insight Report" highlights the details around VERZENIO, which is a targeted treatment known as ...

U.S. President Donald Trump has issued a memorandum directing federal agencies to restrict inbound and outbound investments ...

The company reported a robust set of numbers for the December quarter of FY25, with its profit nearly doubling year-on-year ...

ADCs are currently at the forefront of cancer treatment, but persistent drug development challenges call for a new approach.

Enhertu already has seven FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and ...

The global breast cancer drugs market size was valued at USD 34.25 billion in 2024 and is projected to reach from USD 37.30 ...

23andMe CEO Anne Wojcicki is attempting to buy her company back for a mere $42 million. It’s a fraction of the company’s ...

The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...

As VERZENIO gains traction in early-stage treatments and broadens its approved uses, its revenue is expected to keep growing. While the global CDK4/6 inhibitor market remains highly competitive ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...

Health updates cover U.S. involvement in WHO meetings, UK approval of Moderna's RSV vaccine, a Texas measles outbreak, FDA ...

Mark Erlander; Chief Executive Officer, Director; Cardiff Oncology Inc. James Levine; Chief Financial Officer; Cardi ...